Pharmacotherapy for self-injurious behavior: Preliminary tests of the D1 hypothesis

Progress in Neuropsychopharmacology and Biological Psychiatry

Volumn 14, Issue SUPPL. 1, 1990, Pages

  Gualtieri, C Thomas ^a   Schroeder, Stephen R ^b  

^a North Carolina Neuropsychiatry   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

aggression; dopamine D1 receptors; fluphenazine; neuroleptics; self injurious behavior

Indexed keywords

DOPAMINE; FLUPHENAZINE; PLACEBO;

ADULT; ARTICLE; AUTOMUTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; ORAL DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGGRESSION; CASE REPORT; FEMALE; FLUPHENAZINE; HUMAN; MALE; MENTAL DISORDERS; PILOT PROJECTS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RESEARCH DESIGN;

EID: 0025651184     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/0278-5846(90)90090-4     Document Type: Article

References (38)

1. The Dopamine D1 Receptor Biochemical & Behavioral Aspects
2. Failure of Naloxone to Reduce Self-Injurious Behavior in Two Developmentally Disabled Females
3. Behavioral Differences Between Neonatal and Adult 6-Hyroxydopamine-Treated Rats to Dopamine Agonists: Relevance to Neurological Symptoms in Clinical Syndromes with Reduced Brain Dopamine
4. Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome
5. Self-Mutilation in Lesch-Nyhan Disease Is Caused by Dopaminergic Denervation
6. The Influence of Neuroleptic Drugs on Prolactin Secretion in Children
7. Rational Pharmacotherapy for Self-Injurious Behavior: Testing the D1 Model
8. Pharmacotherapy for Self-lnjurious Behavior: Preliminary Tests of the D1 Hypothesis
9. A Biochemical Basis for Self-Injury
10. Naltrexone Decreases Self-Injurious Behavior
11. A Potent Benzazepine Antipsychotic With Unique Interactions on Dopaminergic Systems
12. A familial disorder of uric acid metabolism and central nervous system function
13. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan Syndrome
14. Low-Dose Haloperidol for Stereotypic Self-Injurious Behavior in the Mentally Retarded
15. Lesch-Nyhan Syndrome Caffeine Model Increase of Purine and Pyrimidine Enzymes in Rat
16. Prophylactic Effect of L-%-Hydroxytrytophan on Self-Mutilation in the Lesch-Nyhan Syndrome
17. Pharmacologic Control of Pemoline Induced Self-injurious Behavior in Rats
18. Self-Injurious Behavior Produced in Rats by Daily Caffeine and Continuous Amphetamine
19. Clonodine Potentiates Drug Induced Self-Injurious Behavior in Rats
20. The Lesch-Nyhan Syndrome
21. Serotonergic Approaches to the Modification of Behavior in the Lesch-Nyhan Syndrome
22. Tryptophan-Trazedone Treatment of Aggressive Behavior
23. Beta-blockers in the Severely and Profoundly Mentally Retarded
24. Naloxone and Self- Mutilation
25. Prevalence of Self-Injurious Behavior in a Large State Facility for the Retarded: A Three-Year Follow-up Study
26. The Definition, Taxonomy, Epidemiology and Ecology of Self-Injurious Behavior
27. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis
28. Brain Dopamine Receptors
29. Lesch-Nyhan Syndrome CSF neurotransmitter abnormalities
30. Current Trends in the Treatment of Self-Injurious Behavior
31. Pharmacological Treatment of Self-Injurious Behavior in Mentally Retarded Persons
32. The Management of Chronic Behavior Disorders in Mentally Retarded Adults with Lithium Carbonate
33. Hypoxanthine-guanine phosphoribosyl-transferase deficiency: the molecular basis of the clinical syndromes